Payment overview · 2025
General Payments
$55.30
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jose Mata
Allopathic & Osteopathic Physicians|Family Medicine · MONROE, WA · NPI 1346227170
Verified facts
What the public records show
CMS Open Payments records show Jose Mata received $55.30 in general payments during 2025 across 2 reported records.
Edwards Lifesciences Corporation accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.29 | 51.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.01 | 48.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $55.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 748 | 214 |
| Losartan Potassium | Losartan Potassium | 395 | 106 |
| Lisinopril | Lisinopril | 394 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 316 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 62 |
| Metformin Hcl Er | Metformin Hcl | 172 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 46 |
| Gabapentin | Gabapentin | 151 | 35 |
| Trazodone Hcl | Trazodone Hcl | 151 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 25 |
| Omeprazole | Omeprazole | 141 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 35 |
| Finasteride | Finasteride | 127 | 31 |
| Alprazolam | Alprazolam | 125 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 21 |
| Simvastatin | Simvastatin | 109 | 29 |
| Glimepiride | Glimepiride | 103 | 29 |
| Allopurinol | Allopurinol | 101 | 28 |
| Eliquis | Apixaban | 101 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 33 |
| Ozempic | Semaglutide | 94 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 13 |
| Furosemide | Furosemide | 89 | 27 |
| Metformin Hcl | Metformin Hcl | 84 | 23 |
| Ezetimibe | Ezetimibe | 83 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Methocarbamol | Methocarbamol | 74 | 17 |
| Spironolactone | Spironolactone | 71 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Jardiance | Empagliflozin | 59 | 18 |
| Montelukast Sodium | Montelukast Sodium | 59 | 15 |
| Sertraline Hcl | Sertraline Hcl | 58 | 18 |
| Atenolol | Atenolol | 57 | 17 |
| Meloxicam | Meloxicam | 54 | 27 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 51 | 51 |
| Carvedilol | Carvedilol | 51 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Prednisone | Prednisone | 43 | 26 |
| Alendronate Sodium | Alendronate Sodium | 42 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 12 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Glipizide Er | Glipizide | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Famotidine | Famotidine | 33 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 17 |
| Topiramate | Topiramate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Azithromycin | Azithromycin | 14 | 14 |
| Fluconazole | Fluconazole | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.30 · 2 records | Edwards Lifesciences Corporation | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error